BRCA2 and neoplasm: Mutagenic treatments may also accelerate the evolution of resistance in the primary tumours, as demonstrated by cisplatin-induced reversion mutations in BRCA2-deficient cancers (34,61), especially if DNA repair deficiencies in the tumours increase the mutagenicity of the treatment (62).